Intrathecal Morphine for Thoracoscopic Surgery
Comparison of the Effects of Intrathecal Morphine at Two Different Doses in Thoracoscopic Lung Resection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Adana, Turkey, 01130
- Cukurova University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- > 18 years old
- ASA class I and II
- Video-assisted thoracoscopic surgery
Exclusion Criteria:
- < 18 years old
- ASA class > II
- Serious hepatic, cardiac, renal, metabolic, endocrine diseases
- Coagulation disfunction
- Allergy to any of the study drugs
- Pneumonectomy
- Infection in the lumbar region
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 10 mcg/kg intrathecal morphine
For postoperative analgesia, before surgical incision, 10 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
|
In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
|
|
Active Comparator: 7 mcg/kg intrathecal morphine
For postoperative analgesia, before surgical incision 7 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
|
In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pain scores
Time Frame: Change from baseline pain scores at 24 hours
|
Postoperative pain scores of the patients were recorded via Visual Analog Scale (VAS; 0= no pain, 10= worst pain)
|
Change from baseline pain scores at 24 hours
|
|
morphine consumption
Time Frame: Change from baseline morphine consumption at 24 hours
|
At the end of surgery, patients were allowed to use the patient controlled analgesia (PCA) device.
The PCA delivered bolus doses of morphine (0.02 mg/kg) every 10 minutes without a backround infusion.
Morphine consumption (mg) was evaluated and recorded postoperative 24 hours.
|
Change from baseline morphine consumption at 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
systolic arterial blood pressure
Time Frame: change from baseline systolic blood pressure at 150 minutes
|
Intraoperative systolic arterial blood pressure (mmHg) values were recorded during surgery.
|
change from baseline systolic blood pressure at 150 minutes
|
|
diastolic arterial blood pressure
Time Frame: change from baseline diastolic blood pressure at 150 minutes
|
Intraoperative diastolic arterial blood pressure (mmHg) values were recorded during surgery.
|
change from baseline diastolic blood pressure at 150 minutes
|
|
mean arterial blood pressure
Time Frame: change from baseline mean arterial blood pressure at 150 minutes
|
Intraoperative mean arterial blood pressure (mmHg) values were recorded during surgery.
|
change from baseline mean arterial blood pressure at 150 minutes
|
|
heart rate
Time Frame: change from baseline heart rate at 150 minutes
|
Intraoperative heart rate (beats/minute) values were recorded during surgery.
|
change from baseline heart rate at 150 minutes
|
|
side effects
Time Frame: postoperative 24 hours
|
All of patients were visited in the thoracic surgery ward after surgery and side effects were evaluated and recorded.
|
postoperative 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ITM1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.